Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Arrowhead Pharmaceuticals, Inc.    ARWR

ARROWHEAD PHARMACEUTICALS, INC.

(ARWR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ARROWHEAD PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

11/23/2020 | 04:07pm EST

Item 2.02 Results of Operations and Financial Condition

On November 23, 2020, Arrowhead Pharmaceuticals, Inc. announced and commented on its fiscal 2020 financial results for the period ended September 30, 2020. A copy of the press release is furnished herewith as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits




Exhibit No.   Description
99.1            Press Release, dated November 23, 2020.




104          Cover Page Interactive File (the cover page tags are embedded within
             the Inline XBRL document).





--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about ARROWHEAD PHARMACEUTICALS, INC.
01/25ARROWHEAD PHARMACEUTICALS : Applies For Investigational New Drug For Investigati..
MT
01/25ARROWHEAD PHARMACEUTICALS : Files IND for Phase 2b Study of ARO-ANG3 for Treatme..
BU
01/19INSIDER TRENDS : 90-Day Insider Buying Trend Reduced with Disposition of Arrowhe..
MT
01/19ARROWHEAD PHARMACEUTICALS : to Webcast Fiscal 2021 First Quarter Results
BU
01/15INSIDER TRENDS : Arrowhead Pharmaceuticals Insider Sale Interrupting 90-Day Buy ..
MT
01/13ARROWHEAD PHARMACEUTICALS : Significant Insider Selling in Shares of Arrowhead P..
MT
01/12INSIDER TRENDS : Arrowhead Pharmaceuticals Insider Sale Scales Back 90-Days of B..
MT
01/11ARROWHEAD PHARMACEUTICALS : Significant Insider Selling Continues at Arrowhead P..
MT
01/08ARROWHEAD PHARMACEUTICALS : Insider Sales at Arrowhead Pharmaceuticals (ARWR) ar..
MT
01/08INSIDER TRENDS : 90-Days of Insider Buying at Arrowhead Pharmaceuticals Eased Ba..
MT
More news